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Abstract

Opioids are among the most common pharmacological class of therapeutic medications
prescribed to alleviate pain across all healthcare settings. However, opioid-related adverse events
are a growing problem contributing to an increase in morbidity and mortality. Current hospital
practice does not utilize a pre-opioid administration screening tool to assess patient risk of
adverse events related to opioid administration. The implementation of the Michigan Opioid
Safety Score (MOSS), an evidence-based risk assessment tool which utilizes patient
characteristics as well as respiratory assessment for the prediction and early detection of opioidinduced adverse events. This quality improvement project evaluated the effectiveness of the
MOSS in detecting opioid-induced adverse events prior to the need for naloxone. The MOSS
was applied to hospitalized patients that experienced an opioid-induced adverse event which
required the use of naloxone to determine if the safety score would have detected an adverse
event prior to current practices. The main finding from the retrospective chart audit identified
that POSS in conjunction with MOSS identifies more patients as at risk for an opioid-related
adverse event than POSS alone, suggesting it would be beneficial to incorporate the MOSS into
its screening process in order to reduce opioid-related adverse events. A secondary finding
identified that scoring unsafe on the risk factors of snoring and abdominal and/or thoracic
surgery on the MOSS were most commonly associated with an opioid-induced adverse event,
suggesting that patients with these risk factors may need increased monitoring practices and
equipment support, such as capnography and the use of BiPAP or CPAP.

Keywords: opioid, capnography, respiratory depression, end tidal CO2, sedation, monitoring
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Implementing use of the MOSS (Michigan Opioid Safety Score) Tool and Interventions to
reduce Opioid-Related Overdose Events in High Risk Patients
Pain, an unpleasant sensory and emotional experience associated with actual or potential
tissue damage, is the most common reason people in the United States (US) seek healthcare
(National Institutes of Health, 2018; Treede, 2018). Opioids are among the most common
pharmacological class of therapeutic medications prescribed to alleviate pain across all
healthcare settings (National Center for Health Statistics, 2017). Although opioids are standard
treatment to assure patient comfort, there are many side effects, ranging from nausea and
vomiting to over-sedation and respiratory depression.
In addition to the reduction of opioid prescribing and efforts to increase multimodal pain
management modalities, The Joint Commission (TJC) has highlighted the importance of
increased screening and respiratory assessment within the population prescribed and
administered opioids (2012). According to TJC Sentinel Event database (2004-2011), 29% of the
opioid-related adverse drug mortality events were related to improper monitoring of a patient. In
response, TJC identified a need for organizations to increase staff awareness of factors which
increase likelihood of accidental opioid over-use, over-sedation, and respiratory depression to
avoid adverse patient outcomes.
Not all hospitals utilize a pre-opioid administration screening tool to assess patient risk of
adverse events related to opioid administration. A screening tool such as the Pasero OpioidInduced Sedation Scale (POSS) and the Richmond Agitation and Sedation Scale are utilized for
assessing a patient’s level of sedation and arousal in the moment (Soto & Yaldou, 2015). Present
standard respiratory assessment entails pulse oximetry combined with respiratory assessment via
observation or auscultation, which has been shown to be less accurate than capnography
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combined with respiratory assessment (Adams, Butas, & Spurlock, 2015; Cacho, Perez-Calle,
Barbado, Lledo, Ojea, & Fernandez-Rodriguez, 2010; Deitch, Miner, Chudnofsky, Dominici, &
Latta, 2010; Hutchison & Rodriguez, 2008). Both practices, retrospective assessment of opioidrelated adverse effects and in-the-moment respiratory assessment, are suboptimal for a patient at
increased risk of opioid related respiratory depression. It is imperative that hospitals institute
proactive screening tools and evidence-based monitoring to prevent opioid related adverse
outcomes such as respiratory depression and death. The purpose of this quality improvement
project was to evaluate the effectiveness of the Michigan Opioid Safety Score (MOSS), a risk
assessment tool, to detect opioid-induced adverse events prior to the need for naloxone in a heart
center in a Midwest hospital (HRT). MOSS is an evidence-based risk assessment tool which
utilizes patient characteristics as well as respiratory assessment for the prediction and early
detection of opioid-induced adverse events.
Assessment of the Organizational
An organizational assessment (OA) utilizes a systematic approach to evaluate the
workflow and factors which impact the performance of an organization (Reflect & Learn, n.d.).
An OA aids in determining areas of strength and weakness within the organization. This
assessment analyzed HRT using a framework, to identify key stakeholders, as well as the
strengths, weaknesses, opportunities, and threats (SWOT) of the organization through a SWOT
analysis.
Framework for Assessment
The Canadian Foundation for Healthcare Improvement (CFHI) assessment tool evaluates
an organization’s capability for change, strengths for implementing change, and potential for
growth (CFHI, 2014). Six core principles aimed at improving healthcare guide CFHI. These
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principles are patient-centered and population-based care, evidence-based decision making,
engaging a wide range of stakeholders, engaging participation from managers and providers,
using an incremental process for large scale improvements, and viewing improvement as a
collective learning process (CFHI, 2014). Appendix A is a visual representation of how the
principles interact in order to improve healthcare (adapted from CFHI, 2018). The key purpose
for utilizing the CFHI assessment tool within the organization was to analyze how effectively the
six principles were exhibited to formulate suggestions for improvements.
The CFHI assessment tool emphasizes the collaboration from all levels within a system,
including policy, organizational, clinical, and front-line staff as important factors for successful
healthcare delivery (CFHI, 2014). CFHI highlights the importance of change cycles for
improvement to maintain stability within the organization. Lastly, CFHI holds the belief that
change within a level of a health system can transcend to the clinical level and affect patient
health outcomes and satisfaction (CFHI, 2014).
Ethics and Protection of Human Subjects
The HRT and the GVSU Institutional Review Board (IRB) determined the project
to be quality improvement (see Appendix B and C).
Stakeholders
Key stakeholders are individuals who affect or are affected by changes within an
organization and are, therefore, either actively or passively impacted by changes in actions,
objectives, or policies within an organization (Moran, Burson, & Conrad, 2017). The key
stakeholders involved in the implementation of an opioid-induced adverse event risk screening
tool, known as the MOSS within HRT, included healthcare providers, such as physicians,
advanced practice providers, fellows, hospitalists, residents, and nurses. Patients were also an
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important stakeholder, since patient safety and outcomes are impacted by changes in policy,
procedure, and practices within an organization. Additional stakeholders include the Pain
Management and Opioid Prescribing Pain Committee at HRT and the information technologists
(IT) who would implement the MOSS screening tool into the electronic health record (EHR).
Lastly, HRT as an organization, was an important key stakeholder. It is important to have buy-in
for the implementation of the MOSS from HRT, as there will be associated cost purchasing
equipment such as capnography as well as education of staff on the use of the MOSS.
SWOT
A SWOT analysis is a tool used to analyze a phenomenon of interest by assessing its
strengths, weaknesses, opportunities, and threats (Moran et al., 2017). Internal analysis includes
identifying an organizations beneficial attributes (strengths) and perceived short-comings or
failures (weaknesses). External analysis includes evaluating threats to an organization’s success
within the environment and identifying possible opportunities for growth or expansion within an
organization (Moran et al., 2017). A SWOT analysis determined the strengths, weaknesses,
opportunities, and threats to implementing the MOSS risk assessment (see Appendix D).
Strengths. One strength was the interest in improving opioid practices and patient safety
within the Pain Management and Opioid Prescribing Steering Committee and MOSS subcommittee. Another strength was that the MOSS is available within the current EHR without the
need for purchase and can easily be installed. Lastly, there was work surrounding issues related
to opioids. As such, investing time and money into MOSS was viewed more favorably at this
time due to its added benefit of meeting TJC standards for accredited hospitals, such as
minimizing risks associated with opioid use (2018).
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Weaknesses. A weakness of HRT was the current assessment tool. The POSS currently
used assessed an individual’s level of alertness in the moment and failed to identify risk of an
opioid related adverse event.
Opportunities. At HRT there was opportunity to be one of the first organizations in the
Midwest to utilize the MOSS. As such, HRT had the opportunity to be at the forefront of
changes in healthcare, taking a proactive role in preventing unnecessary morbidity and mortality
related to opioid use. Another opportunity was improving staff education on patient risk factors
for opioid induced adverse outcomes and empower staff to care for this population.
Threats. A threat to HRT was that, without addressing TJC standards, the hospital risks
loss of Magnet® status and accreditation. As previously discussed, one of TJC standards is to
“actively engage medical staff and hospital leadership in improving pain assessment and
management, including strategies to decrease opioid use and minimize risks associated with
opioid use” (TJC, 2018, p. 1). Loss of accreditation would result in a financial loss and damage
to the organization’s reputation.
Clinical Practice Question
The following clinical questions were answered: “Does the MOSS, in conjunction with
the POSS, detect the opioid-induced adverse event of respiratory depression more effectively
when compared to the POSS alone?”, as well as, “Does the use of capnography and assessment
of respiratory movement, as indicated by the MOSS for opioid-induced sedation, more
efficaciously and accurately detect opioid-induced respiratory depression events compared to
assessment of respiratory movements and monitoring with pulse oximetry?”
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Review of the Literature

Due to the current lack of randomized-controlled trials on use of the MOSS, the literature
review answered the question: “Does the use of capnography and assessment of respiratory
movement, as indicated by the MOSS for opioid-induced sedation, more efficaciously and
accurately detect opioid-induced respiratory depression events compared to assessment of
respiratory movements and monitoring with pulse oximetry?”
Method
Search methods. The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guideline served as the framework for this review (Moher, Liberati,
Tetzlaff, Altman, & PRISMA Group, 2009). A comprehensive search was conducted in the
CINAHL, PubMed, and Medline database limited to English language during 2008 to 2018.
Keywords were opioid, capnography, and respiratory depression. Similar search terms, end tidal
CO2, sedation, and monitoring were listed by using Boolean operator OR, and the Boolean
operator AND was used to narrow articles that were relevant to the review.
Inclusion and Exclusion Criteria
Population. Included were articles that featured adults age 18 or older who underwent
any procedure which necessitated sedation, such as colonoscopy and transesophageal
echocardiogram (TEE), and compared the difference in detection time of respiratory depression
between capnography and pulse oximetry. Excluded were articles that featured adults with
chronic lung disease, such as chronic obstructive pulmonary disease, chronic oxygen
requirements, patients on ventilators, and patients in respiratory distress prior to sedation.
Intervention. Randomized controlled trials that involved pulse oximetry as the control
and capnography as the primary intervention for assess respiratory depression were included.
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Articles that did not utilize and compare both capnography and pulse oximetry to evaluate for
respiratory depression were excluded.
Comparison. Articles that were selected compared capnography to pulse oximetry.
Excluded were articles that used equipment other than pulse oximetry and capnography to
monitor respiratory status.
Outcome. Included were outcomes on the efficacy of capnography in detecting
respiratory depression compared to pulse oximetry. Excluded were outcomes involving the
comparison of other means of assessing respiratory function other than capnography and pulse
oximetry.
Search Outcomes
The search yielded a total of 168 articles. One hundred duplicates were removed. Each
review was screened using inclusion and exclusion criteria according to PRISMA criteria,
eliminating 54 articles (Moher et al., 2009). Review of titles and abstracts resulted in removal of
10 articles that did not meet the inclusion criteria. The remaining four articles were included in
this review (see Appendix E).
Summary of Results
Four articles met the inclusion criteria and were included (see Appendix F). All studies
were randomized controlled trials comparing the efficacy of capnography to pulse oximetry in
detecting respiratory depression in the procedural and post-procedural population. Respiratory
depression definitions slightly varied between the four studies included. The parameters for
respiratory depression were an SpO2 of 88-93%, end-tidal CO₂ level greater than 50-60 mmHg,
an ETCO₂ change from baseline greater than 10 mmHg, or loss of ETCO₂ waveform for greater
than or equal to 15 seconds.

OPIOID RISK ASSESSMENT

13

Study characteristics. Articles included were randomized control trials comparing
capnography and pulse oximetry for the detection of respiratory depression in patients
undergoing procedures requiring sedation such as a TEE and colonoscopy. All articles were
obtained from peer-reviewed journals. Population samples within the four studies utilized varied
from 50-200 participants. All patients were at least 18 years of age or older. In all four studies,
no statistically significant differences in patient demographic characteristics was observed.
Assessment of respiratory function and detection of respiratory decline was monitored during
and after sedation in various hospital settings, such as the emergency department and endoscopy
department, for various procedures, such as TEE, colonoscopy, and orthopedic surgeries.
Intervention and comparison characteristics. Capnography was compared to pulse
oximetry in all studies. All studies compared the efficacy of capnography to pulse oximetry. Two
of the studies utilized pulse oximetry with blinded capnography versus capnography alone
(Adams, Butas, & Spurlock, 2015; Deitch, Miner, Chudnofsky, Dominici, & Latta, 2010). The
other two studies compared capnography alone versus pulse oximetry alone (Cacho, Perez-Calle,
Barbado, Lledo, Ojea, & Fernandez-Rodriguez, 2010) and capnography alone versus pulse
oximetry combined with respiratory assessment via observation or auscultation (Hutchison &
Rodriguez, 2008).
Measures. Respiratory depression was measured in all studies by reporting the number
of detected events as outlined by the study guidelines and definitions of respiratory depression.
Hutchinson and Rodriguez (2008) found that respiratory depression was defined as a respiratory
rate of equal to or less than six breaths per minute, an apneic event lasting longer than 20
seconds, an end-tidal CO₂ level greater than 60 mmHg, or SPO₂ less than 88%. Respiratory
depression in the study by Adams, Butas, and Spurlock (2015) defined respiratory depression as
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an end-tidal CO₂ level of greater than or equal to 50 mmHg, an end-tidal CO₂ change from
baseline greater than 10 mmHg, or a loss of end-tidal CO₂ waveform for greater than or equal to
15 seconds. Deitch et al. (2010) reported that respiratory depression was defined as an SPO₂
level of less than 93% for 15 seconds or greater, an ETCO₂ level of 50 mmHg or greater, an
ETCO₂ increase or decrease from baseline of 10% or greater, or a loss of ETCO₂ waveform for
15 seconds or greater. Cacho et al. (2010) defined respiratory depression as a cessation of
respiratory activity for 30 seconds or more, end-tidal CO₂ change from baseline greater than
25%, or an SpO₂ value less than 90%.
Efficacy of capnography. All four studies reported a statistically significant increase in
detection of respiratory depression in the capnography group compared to the pulse oximetry
group. Deitch et al. (2010) reported that 17 patients in the non-blinded capnography group and
27 patients in the blinded capnography group experienced respiratory depression with an SpO₂
level of less than or equal to 93%. Within the same study, more physician interventions occurred
within the non-blinded capnography group to improve respiratory function (35%) versus the
blinded capnography group (22%). In the study by Cacho et al. (2010), blinded capnography
detected 29 episodes of respiratory depression in 16 patients, whereas pulse oximetry detected
oxygen desaturation in only 38% of those episodes. Adams, Butas, and Spurlock (2015) reported
that of the 90 patients who had respiratory depression based on ETCO₂ readings, SpO₂ at the
time of respiratory depression was M=96.8%, with only 5 patients showing an SpO₂ of 91% or
less. In the study by Hutchinson and Rodriguez (2008), a total of 146 episodes of respiratory
depression were detected within the capnography group, whereas respiratory depression was
detected in only six patients in the pulse oximetry group.

OPIOID RISK ASSESSMENT

15

Evidence to be used for Project
Respiratory depression as a result of a procedure with sedation and analgesia is the
primary cause of morbidity within the procedural and post-procedural population (Cacho et al.,
2010; Deitch et al., 2010; Hutchinson & Rodriguez, 2008). Current practice for respiratory
assessment prior to and after procedure includes basic respiratory monitoring using assessment
of respiratory movements and monitoring with pulse oximetry (Cacho et al., 2010). Findings of
this literature review suggest that capnography is more effective in detecting respiratory
depression than pulse oximetry in the procedural and post-procedural population. In addition,
two of the four studies in this review indicated physicians were more likely to intervene to
reverse respiratory depression when capnography was used to assess respiratory status (Adams,
Butas, & Spurlock, 2015; Deitch et al., 2010).
Phenomenon Conceptual Model
Conceptual models guided understanding of a phenomenon. The phenomenon of interest
for this quality improvement project is opioid-induced adverse events, more specifically opioidinduced respiratory depression. A conceptual model that will be used to provide structure for this
phenomenon of interest is Marion Good’s Theory of Balance Between Analgesia and Side
Effects (Good, 1998). The theory has three areas of nursing action to minimize pain as well as
potential adverse events: multimodal therapy, attentive care, and patient participation (see
Appendix G). The goal of Good’s theory is to appropriately treat pain without the experience of
side effects.
Multimodal therapy. The first area of the theory focuses on the nurse combining potent
pain medications, such as opioids, with non-opioid pain medications and nonpharmacological
therapies as adjuvants (Good, 1998). Potent pain medications are the major method of pain relief
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utilized within the acute care setting, however, they are also the most likely to cause side effect.
Non-opioid pharmacological adjuvants may be given safely along with potent pain medications
to help alleviate pain symptoms because their unrelated mechanism of action increases relief
while not compromising safety. Lastly, nonpharmacological adjuvants, such as relaxation
techniques, heat and cold, repositioning, or music therapy, may be used to distract the patient
from their pain and increase their comfort without any side effects. As explained by the first area
of Good’s theory (Good, 1998), utilizing non-opioid pharmacological adjuvant and
nonpharmacological adjuvant therapies in combination with potent pain medications can
decrease pain as well as minimize the risk of side effects.
Attentive care. The second area of the theory focuses the nurse’s responsibility to
regularly assess for pain and side effect, identify inadequate relief of pain and unacceptable side
effects, and intervene based on assessment findings (Good, 1998). According to Good’s theory
(1998), nurses are responsible for utilizing both verbal and non-verbal reports of pain, treating
the pain based on intensity and patient and situational characteristics, and reassessing the patient
for relief of pain and side effects. In line with this theory, the purpose of this project is to
implement the MOSS in order to increase provider ability to relieve pain symptoms and
minimize risks of side effects through the use of regular assessment.
Patient participation. The final area of the theory focuses on the nurse establishing a
relationship and goals with the patient in order to achieve the mutual goal of relief of pain
symptoms without adverse side effect occurrence (Good, 1998). According to Good’s theory
(1998), the nurse is responsible for providing patient teaching about the causes of pain,
modalities of pain relief, and potential side effects of interventions. The nurse should also
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determine a mutual and realistic goal for pain relief with the patient. Patient participation is
essential in achieving acceptable relief of pain symptoms and minimizing the risk of side effects.
Project Plan
Purpose of Project and Objectives
The goal of this project was to decrease the occurrence of opioid-induced adverse events
using a risk assessment tool. The current tool used at HRT did not assess for patient
characteristics which increase the risk of adverse event occurrence. Thus, this project examined
if the MOSS detects opioid-induced adverse events of respiratory depression more effectively
when combined with the POSS compared to the POSS alone.
Design for the Evidence-based Initiative
Quality improvement projects involve systematic activities designed to monitor, assess,
and improve the quality of healthcare (Health Resources and Services Administration, 2011).
This project focused on the retrospective application of the MOSS to determine if the MOSS is
more effective at detecting risk of opioid-induced adverse events, specifically respiratory
depression. The project also examined if the screening tool detects risk of opioid-induced
adverse events, the MOSS will be applied retrospectively via chart audit to patient’s that
received naloxone to determine if the MOSS would have classified the patient as being at high
risk for an adverse-opioid event, thus cueing the provider to intervene, preventing an adverse
event.
Setting
The setting was a heart center in a Midwest hospital (HRT). The organization, HRT, is
composed of nine floors with 162 beds. The floors range in acuity from intensive care units to
progressive care units. Administrative approval obtained from the organization (see Appendix
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B).
Participants
Patients that received naloxone within HRT between August 1st, 2018 to December 31st,
2018 were included.
Model Guiding Implementation
The model guiding implementation was the Institute for Healthcare Improvement (IHI)
Plan Do Study Act (PDSA) cycle (see Appendix H). The PDSA model is useful for
documenting and testing a proposed change (IHI, 2017).
Plan. The plan phase of PDSA includes stating a clinical question, predicting the
outcome of a proposed intervention, developing a plan to test the practice change, and
identifying what data needs to be collected (IHI, 2017). The predicted outcome was that the
MOSS will identify patients at risk for opioid-induced adverse events and cue providers to
intervene appropriately, ultimately reducing the number of opioid-induced adverse respiratory
depressive events. The plan was to validate the risk assessment tool for opioid-induced
respiratory events includes retrospectively applying the MOSS to patients administered
naloxone.
Do. The do step of PDSA includes piloting the intervention on a small scale with data
collection and analysis (IHI, 2017). A chart audit was performed of patients administered
naloxone to determine the severity of the problem within HRT.
Study. During the study phase of PDSA, results are analyzed and compared to original
predictions (IHI, 2017). The MOSS was applied to the patient’s that were administered
naloxone. Data were analyzed to determine if the MOSS is more sensitive in the detection of
patients at risk for opioid-induced adverse events at HRT than the POSS.
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Act. The final stage of PDSA entails the decision to adapt, adopt, or abandon the change
before starting a new cycle in the plan phase of PDSA (IHI, 2017). Adapting the change involves
making modifications and running another test. Adopting the change involves testing the change
on a larger scale. Abandoning the change involves changing the idea altogether (IHI, 2017).
Implementation Steps and Strategies
According to Powell et al. (2015), there are evidenced-based implementation strategies
used within the implementation of a project, including: readiness assessment and identifying
barriers, capturing and sharing knowledge and creating a collaborative, and consultation and
tools for quality improvement. Each will be discussed.
Readiness assessment and identifying barriers. An organizational assessment and
SWOT analysis were completed in order to assess readiness for change as well as identify
barriers (Powell et al., 2015). The assessment identified strategies for implementation.
Capturing and sharing knowledge and creating a collaborative. Strategies utilized
included capturing and sharing knowledge, organizing implementation team meetings, and using
an implementation advisor (Powell et al., 2015). Capturing and sharing knowledge are aspects of
ongoing implementation strategies at HRT. HRT has a Pain Management and Opioid Prescribing
Steering Committee as well as a MOSS subcommittee which advocate for and drive practice
changes surrounding the safe use of opioids. These committees have chairs appointed, which
oversee the implementation of practice change related to opioid prescribing and safety.
Consultation and tools for quality improvement. The project re-examined
implementation, provided consultation, and developed tools for quality monitoring (Powell et al.,
2015). Re-examining risk assessment strategies were completed to understand the severity of the
opioid-induce adverse reaction rate at baseline. Consultation with HRT based on findings in
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literature and naloxone events found through chart audits occurred. Retrospective application of
the MOSS to patient’s that had naloxone events in order to determine if MOSS is more sensitive
in the detection of individuals at risk for opioid-induced adverse events than the POSS occurred
and was reported to HRT.
Measures
Measures utilized for gauging the project success are shown in Appendix I. The measures
that are necessary to determine the MOSS include assessing patient health risk, respiratory rate,
and modified POSS (Soto & Yaldou, 2015). Patient health risk items included obstructive sleep
apnea, snoring, body mass index greater than 40, same stay abdominal or thoracic surgery,
anesthesia time greater than 3-hours within the last 24-hours, concomitant sedatives received
within the last 2-hours, age greater than 75 years, and current smoker. Respiratory rate was
assessed as a rate of 10 breaths or more per minute or less than 10 breaths per minute. The
modified POSS assessed whether the patient is excessively sedated, drifts off to sleep, difficult to
arouse or unarousable.
Data Collection and Management
Data were collected through chart review on patients that were administered naloxone
over six months.
Data in Appendix I were collected from the EHR and placed in an Excel datasheet on the
internal site drive. Next, data in the excel datasheet will be de-identified. Data were kept on a
secure network password protected internal drive at the site that is accessible by members on the
team from HRT.
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Analysis
Data were analyzed using Statistical Analysis System (SAS) version 9.4 (statistical
software) to determine if the MOSS detected opioid-induce adverse event prior to naloxone
event. Factor analysis using Fisher’s Exact Test will compare the proportion of risk factors that
are most sensitive to scoring patient’s as a risk for an opioid-related event within the MOSS,
with a p-Vaule of less than 0.05 demonstrating a significant difference. A head-to-head
comparison of MOSS to POSS will provide data on whether or not the difference in detection
using MOSS compared to POSS is significant using McNemar’s Test, with a p-Value of 0.05
demonstrating a significant difference.
Factor analysis. A factor loading of the following variables: does the patient have
obstructive sleep apnea, does the patient snore, is the patient’s body mass index greater than 40,
did the patient have abdominal or thoracic surgery during the current hospital stay, were they
under anesthesia for more than three hour or undergo anesthesia within the last 24 hours, have
they received concomitant sedatives within the last 2 hours, are they older than 75 years of age,
are they a smoker, is there respiratory rate 10 breaths per minute or greater, and are they
excessively sedated, drifting off to sleep, or difficult/unable to arouse will be conducted (see
Appendix I).
Resources & Budget
Resources for this project include the DNP student’s time, the Pain Management and
Opioid Prescribing Steering Committee and MOSS subcommittee, providers, pharmacists, and
RNs. Further resources for this project include organizational support such as the facility itself,
computers, and EHR access (see Appendix J). The DNP student is filling a need for the
organization at no cost other than use of staff time to provide information or data related to the
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project. The site staff involved in this project have approved time to put towards this project as
part of their roles.
Timeline
See Appendix K for timeline. Institutional Review Board (IRB) approvals were obtained
from the site and university (see Appendix B and C). The groundwork (i.e. performing an
organizational assessment and completing a literature review) for the project was completed on
November 13, 2018. Data collection concluded January 31st, 2018 and was analyzed. Data was
presented to a MOSS subcommittee member on February 15, 2018. A sustainability plan was
created and final defense occurred on April 17, 2019.
Results
A total of 25 naloxone cases related to adverse opioid-induced respiratory depression
occurred at HRT between August 1st and December 31st, 2018. The MOSS was applied to all 25
cases retrospectively via chart audit.
Demographics
Demographics are shown in Appendix L. Mean age was 70.5 years (Standard Deviation
[SD] 12.3) ranging from 34 years of age to 89 years of age. Of those audited, 77.3% (n=17) were
Caucasian, 4.6% (n=1) were African American, and 18.2% (n=4) were other. Ethnicity were
12% (n=3) Hispanic and 88% (n=22) non-Hispanic. Mean length of stay was 11.9 days (SD 9.7),
ranging from 1 to 35 days. The majority received naloxone in the ICU (n=13, 52%), 8% (n=2)
were transferred to the ICU after naloxone administration, and 40% (n=10) remained on their
current non-ICU unit. Intubation post-naloxone was required by 8% (n=2) of patients and was
not required by 76% (n=19) patients.
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Factors Analyzed
Patient factors analyzed in the MOSS, and thus in this quality improvement project,
included presence of obstructive sleep apnea, snoring, body mass index greater than 40, same
stay abdominal or thoracic surgery, anesthesia time greater than 3-hours within the last 24-hours,
concomitant sedatives received within the last 2-hours, age greater than 75 years, and current
smoker. Respiratory rate is assessed as a rate of 10 breaths or more per minute or less than 10
breaths per minute. The modified POSS assess whether the patient is excessively sedated, drifts
off to sleep, difficult to arouse, or unarousable.
Fisher’s Exact Test was used to compare the proportion of risk factors between patients
that scored as safe (MOSS <2) versus unsafe (MOSS >2) using MOSS. A p-Value less than 0.05
using Fisher’s Exact Test is statistically significant. Two factors, snoring (p=.0119) and
abdominal and/or thoracic surgery (p=.0055), were significant results and were the most frequent
risk factors to score as unsafe by the MOSS compared to all other factors (see Appendix M). As
such, people who scored as at risk for an opioid-related overdose event were more likely to have
the risk factors of snoring and abdominal thoracic surgery compared to any other risk factor.
Comparison of POSS to MOSS
An overall comparison of the sensitivity of the POSS to the MOSS was conducted in
order to determine if combining the MOSS with the POSS would result in the increased
identification of more people at risk for an opioid-related adverse event. McNemar’s Test was
used to compare the sensitivity of POSS versus MOSS (see Appendix N). The results from
McNemar’s test showed evidence (S=7.1429, p=0.0075) against the hypothesis that the two
marginal totals for each risk scale are the same. Therefore, a higher proportion of patients
flagged as at risk for an opioid-related event with MOSS than with POSS. Lastly, findings of the
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McNemar’s test indicate that 20 out of 25 (80%) patients that had an opioid-related event would
have been flagged as at risk for an opioid-related adverse event rather than 8 of 25 (33.3%) with
POSS alone or 18 or 25 (75%) with MOSS alone. Therefore, POSS in conjunction with MOSS
flags more patients as at risk for an opioid-related adverse event than POSS or MOSS alone (see
Appendix O).
Discussion
The main finding from the retrospective chart audit identified that POSS in conjunction
with MOSS identified more patients as at risk for an opioid-related adverse event than a POSS or
a MOSS alone. This suggests that it would be beneficial for HRT to incorporate the MOSS in the
screening process in order to identify more patients at risk for an opioid-related adverse event.
The POSS should continue to be utilized for in the moment assessment of patient’s receiving
opioids and POSS combined with MOSS should be utilized on a regular basis in order to assess
patient risk factors and monitor their level of sedation.
A secondary finding identified that scoring unsafe on the risk factors of snoring and
abdominal and/or thoracic surgery on the MOSS were most commonly associated with an
opioid-induced adverse event. This suggests that patient’s that score on these risk factors within
the MOSS may need increased monitoring and equipment support, such as capnography and the
use of BiPAP or CPAP.
As a result of these finding, HRT is planning to adopt the use of the MOSS into practice.
As such, the MOSS Committee is meeting with stakeholders in order to finalize approval,
discuss practice change, discuss equipment needs, identify strategies for staff education, and
attain budget approval. Additional chart audits have been completed by staff members with the
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help of the DNP student in order to gauge equipment needs. Also, changes to policy which
reflect the interventions implicated by the MOSS are being discussed.
Limitations
Due to the data collection procedures reliance on accurate and timely charting by the
registered nurse, there were instances of missing data present during the retrospective chart audit.
Therefore, these values were unavailable for scoring within the MOSS and subsequent analysis.
Missing data was excluded from final results in order to keep results as accurate as possible.
Another limitation was the small sample size. It was originally predicted that the sample
size would be between 30-50 naloxone cases within HRT. However, after the original pool of
cases were reviewed, cases were excluded based on location outside of HRT and circumstances
that were unrelated to opioid-induced respiratory depression. After exclusions, the final number
of remaining naloxone cases was 25. This number of cases was verified as an adequate sample
size by the statistician for analysis of patient factors as well as sensitivity comparison between
the POSS and the MOSS.
Conclusion
Pain is the most common reason people in the United States (US) seek healthcare and
opioids are among the most common pharmacological class of therapeutic medications
prescribed to alleviate pain across all healthcare settings (National Institutes of Health, 2018;
Treede, 2018; The National Center for Health Statistics, 2017). Although opioids are standard
treatment to assure patient comfort, there are many side effects, ranging from nausea and
vomiting to over-sedation and respiratory depression.
According to TJC Sentinel Event database (2004-2011), 29% of the opioid-related
adverse drug mortality events were related to improper monitoring of a patient, identifying a
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need for organizations to increase staff awareness of factors which increase likelihood of
accidental opioid over-use, over-sedation, and respiratory depression to avoid adverse patient
outcomes.
Not all hospitals utilize a pre-opioid administration screening tool to assess patient risk of
adverse events related to opioid administration, but rather screening tools, such as the POSS,
which assess the patient’s level of sedation and arousal in the moment after opioid administration
has already occurred (Soto & Yaldou, 2015). Present standard respiratory assessment entails
pulse oximetry combined with respiratory assessment via observation or auscultation, which has
been shown to be less accurate than capnography combined with respiratory assessment (Adams,
Butas, & Spurlock, 2015; Cacho, Perez-Calle, Barbado, Lledo, Ojea, & Fernandez-Rodriguez,
2010; Deitch, Miner, Chudnofsky, Dominici, & Latta, 2010; Hutchison & Rodriguez, 2008).
Both practices, retrospective assessment of opioid-related adverse effects and in-the-moment
respiratory assessment, are suboptimal for a patient at increased risk of opioid related respiratory
depression. It is imperative that hospitals institute proactive screening tools and evidence-based
monitoring to prevent opioid related adverse outcomes such as respiratory depression and death.
The purpose of this quality improvement project was to evaluate the effectiveness of the
MOSS to detect opioid-induced adverse events prior to the need for naloxone in a heart center in
a Midwest hospital (HRT). MOSS is an evidence-based risk assessment tool which utilizes
patient characteristics as well as respiratory assessment for the prediction and early detection of
opioid-induced adverse events.
The main finding from the retrospective chart audit identified that POSS in conjunction
with MOSS identified more patients as at risk for an opioid-related adverse event than POSS
alone, suggesting it would be beneficial for HRT to incorporate the MOSS into its screening

OPIOID RISK ASSESSMENT

27

process in order to identify more patients at risk for an opioid-related adverse event. A secondary
finding identified that scoring unsafe on the risk factors of snoring and abdominal and/or thoracic
surgery on the MOSS were most commonly associated with an opioid-induced adverse event,
suggesting that patients with these risk factors may need increased monitoring practices and
equipment support, such as capnography and the use of BiPAP or CPAP.
As a result of these finding, HRT is planning to adopt the use of the MOSS into practice.
Next steps include finalizing approval, discussing practice change, determining equipment needs,
identifying and compiling education for staff, and attaining budget approval. Changes to policy
which reflect the interventions identified by the MOSS also need to be addressed prior to
implementation.
Implications for Practice and Further Study in the Field
Increased identification and monitoring practices for patients that are at risk for opioidrelated adverse events are imperative in order to increase patient safety. Evidence demonstrates
that current practices surrounding opioid monitoring strategies are suboptimal and that there is a
need for a more proactive approach to decreasing adverse outcomes. This project revealed that in
HRT, POSS combined with MOSS was more effective than the POSS, or the MOSS, alone in
identifying patients at risk for an opioid-related adverse outcome. Future projects should include
practice change strategies aimed at reducing opioid-induced adverse events after patients have
been identified as at risk.
Sustainability Plan
Sustainability of this DNP project includes the following. First, pending results of the
MOSS quality improvement project, providers (physicians, nurse practitioners, physician
assistants, and nurses) will need to be educated on the MOSS. Next, IT will install the MOSS
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into the EHR for use in addition to the POSS. Additionally, the organization will need to assess
inventory numbers for equipment such as capnography and BiPAP/CPAP and purchase
additional equipment if necessary. Lastly, the Pain Management and Opioid Prescribing Steering
Committee and MOSS subcommittee will continue to monitor the effectiveness of the MOSS
after the DNP student has completed the project.
Dissemination of Results
Results of the retrospective chart audit from the MOSS Project will be summarized and
presented to both the Pain Management and Opioid Steering Committee and MOSS
Subcommittee. Results will also be displayed in a poster presentation format at the Spectrum
Health Research Council Poster Display on April 9th, 2019. Lastly, a formal defense presentation
will take place on April 17th, 2019, in which results will be disseminated to project mentors,
advisors, and all other interested and involved parties.
Reflection on DNP Essentials
The American Association of Colleges of Nursing (AACN) require that DNP students are
proficient in the following 8 foundational competencies that are essential for advanced nursing
practice roles. Each is reviewed.
Essential I: Scientific Underpinnings for Practice
The DNP learns to integrate nursing science with knowledge from multiple sciences, use
theory to guide practice and enhance health care delivery, evaluate the outcomes, and develop
new practice approaches (AACN, 2006). This essential was achieved through this project by
preforming a literature search on current monitoring practices of patients that receive opioids
within the hospital setting to improve patient safety. In addition, Marion Good’s Theory of
Balance Between Analgesia and Side Effects was used as frameworks for guiding change.
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Essential II: Organizational and Systems Leadership
Leadership within organizations and systems is necessary to improve practice. This
essential focuses on assessing organizations, identifying system issues, and working to facilitate
changes in practice delivery to improve health outcomes and patient safety (AACN, 2006). The
student demonstrated organizational and systems leadership by meeting with leaders and other
stakeholders throughout the system and performing an organizational needs assessment of HRT
related to naloxone events. This information was then used to determine if the MOSS in
combination with the POSS would flag more patients at risk for a opioid-induced adverse event,
leading staff members to increase and improve monitoring practices for these patients prior to
event occurrence. Leadership and communication skills were used to assess barriers and
facilitators, listen to staff and stakeholder ideas, and work with staff to encourage
implementation. The student also went through the process of creating a budget for this project
as well as submitting the project proposal to the organization and university HRRC committee
which deemed it a non-research, quality improvement project.
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
An essential role of DNP graduates is to translate research into evidence-based practice.
This involves using analytic methods to evaluate evidence, applying relevant findings for
improvement of healthcare practices and outcomes, and participation in knowledge generation
and collaborative research (AACN, 2006). The student used analytic methods to evaluate
literature regarding the best evidence for patient respiratory monitoring practices during and after
opioid administration and to analyze current naloxone event rates within the organization. The
project included applying the MOSS retrospectively to individuals that experienced an opioidrelated adverse event which necessitated the use of naloxone and determining if the MOSS
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would have flagged the patient at risk prior to the event occurring. This quality improvement
project was put in place to provide safe, patient-centered care. Information technology in the
form of the EHR and Excel was used to extract, organize, and analyze data related to naloxone
event occurrence and MOSS scoring.
Essential IV: Information Systems Technology
DNP graduates must be proficient in the use of, selection of, and evaluation of
information systems and technology resources to support practice and improve care. This
includes the related ethical, regulatory, and legal issues that come with the use of information
and systems technology (AACN, 2006). For this project the student used the organization’s EHR
to gather data on naloxone event rates as well as patient information needed for MOSS scoring.
E-mail was used for communication with stakeholders. Excel was used for organizing and
analyzing data. The student was careful to follow all ethical guidelines and maintain strict
confidentiality of any identifiable patient data.
Essential V: Advocacy for Health Care Policy
Heath care policy, at any level, creates a framework that can either help or impeded the
ability to address health care needs by delivering high-quality health care services. Therefore,
advanced practice nurses must be engaged in the process of policy development and advocacy
for good health care policy. During this project the student took into account the organization’s
current policy and practices related to the monitoring of patients receiving opioids and the
evidence regarding patient monitoring in the literature to improve current practice. This project
did not include a policy change, but rather helped to create a foundation for future policy
changes.
Essential VI: Interprofessional Collaboration
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This essential emphasizes the importance of collaborative practice between multiple
healthcare specialties in today’s healthcare climate (AACN, 2006). DNP graduates must be able
to work in and lead collaborative teams of professionals in order to develop and implement
practice models that deliver excellent patient-centered care. For this project the DNP student met
with many different professionals in the health-care system including physicians, NPs, PAs,
RNs, managers, researchers, quality improvement data specialist, CNSs, and pharmacists.
Communicating and working with different disciplines allowed the student to understand the
current practice, evaluate needed changes, assess barriers and needed facilitators, and gain other
important input in order to complete the quality improvement project.
Essential VII: Clinical Prevention and Population Health
DNP graduates have knowledge regarding clinical prevention and population health
including the ability to analyze epidemiological, biostatistical, occupational, and environmental
data in order to develop, implement, and evaluate care delivery models and strategies for clinical
prevention and population health (AACN, 2006). This project was focused on prevention for
better population health. Opioid-Induced adverse events are a population health issue which can
result in morbidity and mortality, added healthcare costs, and longer hospital stays for patients.
Assessing patients for risk factors for an opioid-induced adverse event prior to opioid
administration allows for providers to adjust practices related to prescribing and monitoring
needs of patients requiring pain medication and safely achieve the balance between analgesia and
side effects.
Essential VIII: Advanced Nursing Practice
This essential specifies the primary practice competencies that are necessary in all
specialties and are a foundation for DNP practice. DNP prepared nurses have the ability to:
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conduct comprehensive and systematic assessments in complex situations; design, implement
and evaluate interventions; develop and sustain relationships with patients and other
professionals in order to provide optimal care; demonstrate systems thinking in order to improve
patient outcomes; and educate and guide others through situational transitions (AACN, 2006).
This project covered all of these competencies. An organizational assessment of current
monitoring practice for patients receiving opioids was performed and systems thinking was used
to select, implement, and evaluate the MOSS. In order to carry out this project many
relationships with various stakeholders, particularly within the Pain Management and Opioid
Prescribing Committee and MOSS Subcommittee, were developed and sustained. The student
completed the retrospective chart audit and disseminated the results to the appropriate
committees in order to collect evidence for practice change.
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Appendices
Appendix A

Appendix A. The Canadian Foundation for Healthcare Improvement Model
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Appendix B

Project Organization IRB Determination Letter
Appendix B. Available upon request.
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Appendix C
GVSU IRB Determination Letter
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Appendix D

Strengths
•
•
•
•

Pain Management and Opioid
Prescribing Committee
MOSS Sub-Committee
MOSS available within EHR
High priority due to TJC standards

Weaknesses
•
•

Opportunities
•
•

Forefront of impactful changes related
to the opioid crisis
Increase education of staff regarding
patient risk factors

Appendix D. SWOT Analysis of the MOSS

POSS based solely on patient’s
current level of alertness
POSS does not consider patient risk
factors

Threats
•
•

Loss of accreditation and Magnet
status
Financial loss and damaged reputation
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Appendix E

Appendix E. PRISMA Flow diagram of search selection process
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Appendix F

Author (Year)
purpose

Design (N)

Adams (2015)
evaluate
usefulness of
capnography
versus pulse
oximetry

Prospective,
single-group,
observational
design
(N=200)

Cacho et al.
(2010)
compare
standard pulse
oximetry with
capnography for
the monitoring
of ventilatory
status during
colonoscopies
under sedation

Prospective
study
(N=50)

Deitch et al.
(2010)
determine
whether
physician use of

Randomized
controlled
trial
(N=132)

Inclusion
criteria

Intervention
vs.
comparison
>18 years old,
Staff-blinded
able to read and capnography
speak English, vs standard
and who were
assessment
alert, oriented, with pulse
and able to
oximetry
provide consent
and adult
patients
undergoing
TEE

Results

Respiratory
depression
developed in
45% (n=90). Of
90, SPO2 at the
time of
respiratory
depression was
M=96.8%
(range 87% to
100%). At the
time that
respiratory
depression was
5 (5.5%) an
SPO2 of ≤91%.
>18 years old,
Capnography Capnography
non-ventilated, vs pulse
detected 29
and no allergies oximetry
episodes of
to sedation
anomalous
and/or
ventilation in
analgesia
n=16, mean 54.4
medications
seconds. Pulse
oximetry
detected oxygen
desaturation in
38% of
episodes. Two
episodes of
disturbed
ventilation were
simultaneously
detected by
capnography
and pulse
oximetry.
>18 years old
Study group
Seventeen
and selected for (standard
patients in the
propofol
monitoring
nonblinded
sedation; no
and
group and 27
history of
capnography) patients in the

Conclusion

Capnography
detected respiratory
depression before
pulse oximetry

Respiratory disorders
during colonoscopies
are detected to a
greater extent and
earlier by
capnography
compared to
conventional pulse
oximetry.

Physicians
performing ED
procedural sedation
with propofol
decreased the rate of
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real-time
capnography
was associated
with 15%
decrease in the
incidence of
hypoxia
compared with
standard
monitoring alone

Hutchison &
Rodriguez.
(2008)
determine
whether
capnography
alone was more
sensitive than
pulse oximetry
with respiratory
rate assessment
by observation
or auscultation
to detect
respiratory
depression

COPD, chronic
oxygen
requirements,
or respiratory
distress and
during ED
procedural
sedation with
propofol

Randomized,
controlled
trial
(N=54)

42
vs control
group
(standard
monitoring
and blinded
capnography)

blinded group
experienced an
SpO2 level of
less than or
equal to 93%.
With
capnography
there were more
physician
interventions to
improve
respiratory
status, 24 of 68
(22%).
Physician’s
Study group
Respiratory
order for opioid (capnography depression was
analgesia and
alone) vs
detected at a
be older than
control group significantly
18 years of age, (monitored
higher rate in
has to be
every four
the capnography
breathing
hours by spot group (P=0.03).
spontaneously
check pulse
In total, 146
(nonventilated), oximetry and episodes of
be without a
respiratory
respiratory
diagnosis of
rate
depression were
OSA, not be
assessment
detected during
using a CPAP
by
the 36 hours:
device, and be
observation
140 in the
able to report a or
capnography
pain intensity
auscultation) group and 6 in
on a 0-10 pain
control group;
rating scale
n=17 (15 in the
capnography
group and two
in the control
group)
accounted for all
episodes of
respiratory
depression.

hypoxic events by
using capnography in
conjunction with
standard monitoring
(17%, p=.035) and
clinically significant.

Capnography was
more effective in
detecting
“subclinical”
respiratory
depression than pulse
oximetry during
procedural sedation.

Appendix F. Articles included in review with author, year, purpose, design, inclusion, results,
conclusions
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Appendix G

Appendix G. Marion Good’s (1998) Theory of Balance Between Analgesia and Side Effects
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Appendix H

Appendix H. Institute for Healthcare Improvement’s Plan Do Study Act Implementation Model
(IHI, 2017). Retrieved from
http://www.ihi.org/resources/Pages/Tools/PlanDoStudyActWorksheet.aspx
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Appendix I

Item
Patient ID
Patient
Demographics

MRN/FIN
DOB

Race

Ethnicity
Medication
Administration Date of naloxone administration
Health Risk
Group 1
Does the patient have OSA?

Measurement
Level
Numeric
Numeric
1=Caucasian
2=African
American
3=Other
1=NonHispanic
2=Hispanic
Numeric

Is the patient a current smoker?

0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)
0=No 1=Yes
(Categorical)

Respiratory
Rate

Is the patient’s respiratory rate less than 10 breaths per minute?

0=No 1=Yes
(Categorical)

Modified
POSS

Is the patient excessively sedated, drifting off to sleep, difficult to
arouse or unable to arouse?

0=No 1=Yes
(Categorical)

Does the patient snore?

Group 2

Group 3

Does the patient have a BMI >40
Did the patient undergo abdominal or thoracic surgery during this
admission?
Was the patient under anesthesia for > 3 hours within the last 24
hours?
Did the patient receive concomitant sedatives within the last 2
hours?

Group 4
Is the patient older than 75 years of age?

Patient MOSS

Appendix I. Table of Measures.

Numeric

Findings
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Appendix J
Budget

Doctor of Nursing Practice Project Financial Operating Plan
Implementing use of the MOSS (Michigan Opioid Safety Score) Tool and Interventions
to reduce Opioid-Related Overdose Events in High Risk Patients at a Heart Center in a
Midwest Hospital
Revenue
Project Manager Time (in-kind donation)
Consultations
Statistician (in-kind donation)
Cost mitigation
Prevention of 1 case of opioid-induced respiratory depression-related Intensive Care Unit
stay with ventilator care for 8 days / per year
TOTAL INCOME

6,200.00
100.00

12,176.00*
18,476.00

Expenses
Project Manager Time (in-kind donation)
Team Member Time:
Clinical Nurse Specialist (1)
Consultations
Statistician (in-kind donation)
TOTAL EXPENSES
Net Operating Plan

* Overdyk, F. J., Dowling, O., Marino, J., Qiu, J., Chien, H. L., Erslon, M., Morrison, N., Harrison,
B., Dahan, A., … Gan, T. J. (2016). Association of opioids and sedatives with increased risk of inhospital cardiopulmonary arrest from an administrative database. PloS one, 11, 1-13.

6,200.00
2,000.00
100.00
8,300.00
10,176.00
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Appendix K
Project Timeline
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Appendix L
Demographics

Characteristic
Age

Mean (SD) Range N=25
70.5 years (12.3)
34.4-89.3 years

LOS

11.9 days (9.7)
1-35 days
% (n)

Race
Caucasian 77.3% (17 of 25)
Other 18.2% (4 of 25)
African American 4.6% (1 of 25)
Ethnicity
Non-Hispanic 88% (22 of 25)
Hispanic 12% (3 of 25)
Transfer to ICU
Already There 52% (13 of 25)
No 40% (10 of 25)
Yes 8% (2 of 25)
Intubated
No 76% (19 of 25)
Already Intubated 16% (4 of 25)
Yes 8% (2 of 25)

Appendix L. Age, hospital length of stay, Race, Ethnicity, transfer to ICU or intubated after
administration of Naloxone.
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Appendix M
Table Frequencies of Risk Factors

Obstructive sleep apnea
Snoring
BMI > 40

Abdominal/Thoracic Surgery
Anesthesia > 3 hours within 24 hours
Concomitant sedatives within 2 hours
Age > 75 years
Current smoker
Respiratory rate <10

MOSS Scored as safe % (n)
(<2)
(>2)
4% (1 of 25) Yes
20% (5 of 25) Yes
20% (5 of 25) No
56% (14 of 25) No
4% (1 of 25) Yes
60% (15 of 25) Yes
20% (5 of 25) No
16% (4 of 25) No
13.6% (3 of 22) No 11.8% (2 of 17) Yes
3 of 25 missing data 53% (9 of 17) No
8 of 25 missing data
4% (1 of 25) Yes
64% (16 of 25) Yes
20% (5 of 25) No
12% (3 of 25) No
24% (6 of 25) No
16% (4 of 25) Yes
60% (15 of 25) No
24% (6 of 25) No
20% (5 of 25) Yes
56% (14 of 25) No
4% (1 of 25) Yes
28% (7 of 25) Yes
20% (5 0f 25) No
48% (12 of 25) No
4% (1 of 25) Yes
20% (5 of 25) Yes
20% (5 of 25) No
56% (14 of 25) No
20.8% (5 of 24) No 4% (1 of 25) Yes
1 of 25 missing data 52% (13 of 25) No

p-Value
1.000
0.0119*
1.000

0.0055*
0.5404
0.2887
0.6237
1.000
1.000

Appendix M. Obstructive sleep apnea, snoring, body mass index greater than 40, same stay
abdominal or thoracic surgery, anesthesia time greater than 3 hours within the last 24 hours,
concomitant sedatives with 2 hours, age greater than 75 years old, current smoker, and
respiratory rate less than 10 breaths per minute.
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Appendix N
Figure Frequencies of Risk Factors

RISK FACTORS IDENTIFIED IN MOSS (YES/NO) BY
MOSS <2 AND >2
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Appendix N. Obstructive sleep apnea, snoring, body mass index greater than 40, same stay
abdominal or thoracic surgery, anesthesia time greater than 3 hours within the last 24 hours,
concomitant sedatives with 2 hours, age greater than 75 years old, current smoker, and
respiratory rate less than 10 breaths per minute.
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Appendix O
Table Comparing MOSS to POSS Identification of Risk

POSS
MOSS
p-Value
66.7% (16 of 25) Safe
25.0% (6 of 25) Safe
0.0075
33.3% (8 of 25) Flagged 75.0% (18 of 25) Flagged

Appendix O. POSS scoring as safe (<2) and POSS scoring unsafe (>2) compared to MOSS
scoring as safe (<2) and MOSS scoring unsafe (>2) within same patient population (n=25).
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Appendix P
Figure Comparing MOSS to POSS Identification of Risk

Graphic Depiction Comparing Percentage of
MOSS to POSS Identification of Risk in Chart Audits (N=25)
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Appendix P. POSS scoring as safe (<2) and POSS scoring unsafe (>2) compared to MOSS
scoring as safe (<2) and MOSS scoring unsafe (>2) within same patient population (n=25).
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